These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 16912035

  • 1. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.
    Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG.
    J Biol Chem; 2006 Oct 13; 281(41):30561-72. PubMed ID: 16912035
    [Abstract] [Full Text] [Related]

  • 2. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
    Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A, Seidah NG.
    Traffic; 2007 Jun 13; 8(6):718-32. PubMed ID: 17461796
    [Abstract] [Full Text] [Related]

  • 3. In vivo evidence that furin from hepatocytes inactivates PCSK9.
    Essalmani R, Susan-Resiga D, Chamberland A, Abifadel M, Creemers JW, Boileau C, Seidah NG, Prat A.
    J Biol Chem; 2011 Feb 11; 286(6):4257-63. PubMed ID: 21147780
    [Abstract] [Full Text] [Related]

  • 4. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
    Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zaïr Y, Nguyen P, Krempf M, Cariou B, Costet P.
    J Biol Chem; 2008 Apr 11; 283(15):9666-73. PubMed ID: 18245819
    [Abstract] [Full Text] [Related]

  • 5. Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation.
    Benjannet S, Hamelin J, Chrétien M, Seidah NG.
    J Biol Chem; 2012 Sep 28; 287(40):33745-55. PubMed ID: 22875854
    [Abstract] [Full Text] [Related]

  • 6. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
    Lipari MT, Li W, Moran P, Kong-Beltran M, Sai T, Lai J, Lin SJ, Kolumam G, Zavala-Solorio J, Izrael-Tomasevic A, Arnott D, Wang J, Peterson AS, Kirchhofer D.
    J Biol Chem; 2012 Dec 21; 287(52):43482-91. PubMed ID: 23135270
    [Abstract] [Full Text] [Related]

  • 7. PCSK9: a key modulator of cardiovascular health.
    Seidah NG, Awan Z, Chrétien M, Mbikay M.
    Circ Res; 2014 Mar 14; 114(6):1022-36. PubMed ID: 24625727
    [Abstract] [Full Text] [Related]

  • 8. Thrombin activation of protein C requires prior processing by a liver proprotein convertase.
    Essalmani R, Susan-Resiga D, Guillemot J, Kim W, Sachan V, Awan Z, Chamberland A, Asselin MC, Ly K, Desjardins R, Day R, Prat A, Seidah NG.
    J Biol Chem; 2017 Jun 23; 292(25):10564-10573. PubMed ID: 28468828
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion.
    Cameron J, Holla ØL, Berge KE, Kulseth MA, Ranheim T, Leren TP, Laerdahl JK.
    FEBS J; 2008 Aug 23; 275(16):4121-33. PubMed ID: 18631360
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
    Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA, Tarachandani A, De Francesco R, Wright SD, Sparrow CP, Carfi A, Sitlani A.
    J Biol Chem; 2007 Jul 13; 282(28):20502-12. PubMed ID: 17493938
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events.
    Benjannet S, Saavedra YG, Hamelin J, Asselin MC, Essalmani R, Pasquato A, Lemaire P, Duke G, Miao B, Duclos F, Parker R, Mayer G, Seidah NG.
    J Biol Chem; 2010 Dec 24; 285(52):40965-78. PubMed ID: 20937814
    [Abstract] [Full Text] [Related]

  • 16. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M.
    J Clin Endocrinol Metab; 2015 Jan 24; 100(1):E41-9. PubMed ID: 25313916
    [Abstract] [Full Text] [Related]

  • 17. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
    Poirier S, Prat A, Marcinkiewicz E, Paquin J, Chitramuthu BP, Baranowski D, Cadieux B, Bennett HP, Seidah NG.
    J Neurochem; 2006 Aug 24; 98(3):838-50. PubMed ID: 16893422
    [Abstract] [Full Text] [Related]

  • 18. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
    Le QT, Blanchet M, Seidah NG, Labonté P.
    J Biol Chem; 2015 Sep 18; 290(38):23385-400. PubMed ID: 26195630
    [Abstract] [Full Text] [Related]

  • 19. Regulation of prohepcidin processing and activity by the subtilisin-like proprotein convertases Furin, PC5, PACE4 and PC7.
    Scamuffa N, Basak A, Lalou C, Wargnier A, Marcinkiewicz J, Siegfried G, Chrétien M, Calvo F, Seidah NG, Khatib AM.
    Gut; 2008 Nov 18; 57(11):1573-82. PubMed ID: 18664504
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.